Characteristics and outcome of chronic myeloid leukemia patients with F317l BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Neeli Reddy, Susan O'Brien, Guillermo Garcia-Manero, Jan Burger, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Mutations in codon 317 after treatment with imatinib and dasatinib have been reported. We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy. F317L was detected in 20, including 12/99 (12%) with mutation after imatinib failure, and 8/16 (50%) after dasatinib (P=.001). Median follow-up from mutation detection was 25 months.At the time of F317L, 8 patients were in chronic phase (CP), 6 in accelerated phase, and 6 in blast phase. There was no difference in characteristics between patients with or without F317Lmutations, or with no mutations. A complete cytogenetic response was acheived in 3 of 6 patients treated with nilotinib, 2 of 2 with imatinib, and 0 of 3 with dasatinib. Survival of patients with F317L was similar to those with other mutations (P = .45). Patients in CP had better outcome, with a 2-year survival of 75%. F317L mutation is resistant to dasatinib but sensitive to other TKIs. The prognosis is dependent mostly on the disease stage.

Original languageEnglish (US)
Pages (from-to)4839-4842
Number of pages4
JournalBlood
Volume112
Issue number13
DOIs
StatePublished - Dec 15 2008

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Phosphotransferases
Mutation
Therapeutics
Blast Crisis
Survival
Dasatinib
Codon
Cytogenetics
Imatinib Mesylate

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Characteristics and outcome of chronic myeloid leukemia patients with F317l BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. / Jabbour, Elias; Kantarjian, Hagop M.; Jones, Dan; Reddy, Neeli; O'Brien, Susan; Garcia-Manero, Guillermo; Burger, Jan; Cortes, Jorge.

In: Blood, Vol. 112, No. 13, 15.12.2008, p. 4839-4842.

Research output: Contribution to journalArticle

Jabbour, Elias ; Kantarjian, Hagop M. ; Jones, Dan ; Reddy, Neeli ; O'Brien, Susan ; Garcia-Manero, Guillermo ; Burger, Jan ; Cortes, Jorge. / Characteristics and outcome of chronic myeloid leukemia patients with F317l BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. In: Blood. 2008 ; Vol. 112, No. 13. pp. 4839-4842.
@article{9868609eafdb414ebe7f50f8bb484066,
title = "Characteristics and outcome of chronic myeloid leukemia patients with F317l BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors",
abstract = "Mutations in codon 317 after treatment with imatinib and dasatinib have been reported. We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy. F317L was detected in 20, including 12/99 (12{\%}) with mutation after imatinib failure, and 8/16 (50{\%}) after dasatinib (P=.001). Median follow-up from mutation detection was 25 months.At the time of F317L, 8 patients were in chronic phase (CP), 6 in accelerated phase, and 6 in blast phase. There was no difference in characteristics between patients with or without F317Lmutations, or with no mutations. A complete cytogenetic response was acheived in 3 of 6 patients treated with nilotinib, 2 of 2 with imatinib, and 0 of 3 with dasatinib. Survival of patients with F317L was similar to those with other mutations (P = .45). Patients in CP had better outcome, with a 2-year survival of 75{\%}. F317L mutation is resistant to dasatinib but sensitive to other TKIs. The prognosis is dependent mostly on the disease stage.",
author = "Elias Jabbour and Kantarjian, {Hagop M.} and Dan Jones and Neeli Reddy and Susan O'Brien and Guillermo Garcia-Manero and Jan Burger and Jorge Cortes",
year = "2008",
month = "12",
day = "15",
doi = "10.1182/blood-2008-04-149948",
language = "English (US)",
volume = "112",
pages = "4839--4842",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Characteristics and outcome of chronic myeloid leukemia patients with F317l BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

AU - Jabbour, Elias

AU - Kantarjian, Hagop M.

AU - Jones, Dan

AU - Reddy, Neeli

AU - O'Brien, Susan

AU - Garcia-Manero, Guillermo

AU - Burger, Jan

AU - Cortes, Jorge

PY - 2008/12/15

Y1 - 2008/12/15

N2 - Mutations in codon 317 after treatment with imatinib and dasatinib have been reported. We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy. F317L was detected in 20, including 12/99 (12%) with mutation after imatinib failure, and 8/16 (50%) after dasatinib (P=.001). Median follow-up from mutation detection was 25 months.At the time of F317L, 8 patients were in chronic phase (CP), 6 in accelerated phase, and 6 in blast phase. There was no difference in characteristics between patients with or without F317Lmutations, or with no mutations. A complete cytogenetic response was acheived in 3 of 6 patients treated with nilotinib, 2 of 2 with imatinib, and 0 of 3 with dasatinib. Survival of patients with F317L was similar to those with other mutations (P = .45). Patients in CP had better outcome, with a 2-year survival of 75%. F317L mutation is resistant to dasatinib but sensitive to other TKIs. The prognosis is dependent mostly on the disease stage.

AB - Mutations in codon 317 after treatment with imatinib and dasatinib have been reported. We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy. F317L was detected in 20, including 12/99 (12%) with mutation after imatinib failure, and 8/16 (50%) after dasatinib (P=.001). Median follow-up from mutation detection was 25 months.At the time of F317L, 8 patients were in chronic phase (CP), 6 in accelerated phase, and 6 in blast phase. There was no difference in characteristics between patients with or without F317Lmutations, or with no mutations. A complete cytogenetic response was acheived in 3 of 6 patients treated with nilotinib, 2 of 2 with imatinib, and 0 of 3 with dasatinib. Survival of patients with F317L was similar to those with other mutations (P = .45). Patients in CP had better outcome, with a 2-year survival of 75%. F317L mutation is resistant to dasatinib but sensitive to other TKIs. The prognosis is dependent mostly on the disease stage.

UR - http://www.scopus.com/inward/record.url?scp=58149380741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149380741&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-04-149948

DO - 10.1182/blood-2008-04-149948

M3 - Article

C2 - 18818391

AN - SCOPUS:58149380741

VL - 112

SP - 4839

EP - 4842

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -